Department of Psychiatry, Fujita Health University School of Medicine, Kutsukake-cho, Toyoake, Aichi, Japan.
Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine, Kutsukake-cho, Toyoake, Aichi, Japan.
J Alzheimers Dis. 2018;66(4):1379-1387. doi: 10.3233/JAD-180888.
A systematic review and meta-analysis of the efficacy/safety of intravenous immunoglobulin (IVIG) administration in mild-to-moderate Alzheimer's disease (AD) patients was performed. Six randomized double-blind, placebo-controlled trials (n = 801) were included in this study. No significant difference in cognitive function was observed between the groups. Moreover, IVIG was inferior to placebo in behavioral disturbances (mean difference = 2.19). Further, IVIG administration was associated with a higher incidence of rash than placebo. Our results do not support IVIG administration for mild-to-moderate AD, suggesting that IVIG is not effective to treat mild-to-moderate AD and that it deteriorates behavioral and psychological symptoms of dementia in mild-to-moderate AD.
一项关于静脉注射免疫球蛋白（IVIG）治疗轻度至中度阿尔茨海默病（AD）患者的疗效/安全性的系统评价和荟萃分析。本研究纳入了 6 项随机双盲、安慰剂对照试验（n=801）。两组间认知功能无显著差异。此外，IVIG 在行为障碍方面劣于安慰剂（均数差=2.19）。此外，IVIG 治疗组皮疹的发生率高于安慰剂组。我们的结果不支持 IVIG 治疗轻度至中度 AD，表明 IVIG 对治疗轻度至中度 AD 无效，反而会加重轻度至中度 AD 患者的行为和心理症状。
